The U.S. solicitor general has urged the Supreme Court to review a Federal Circuit decision that requires some biosimilar makers wait six months after receiving FDA approval to launch a product.
Source: Generic Line
The U.S. solicitor general has urged the Supreme Court to review a Federal Circuit decision that requires some biosimilar makers wait six months after receiving FDA approval to launch a product.
Source: Generic Line